Investor insights
Sectors invested in
Funding rounds participated in
$23M sweet spot round size
Most of their 151 investments are in rounds between $21M and $51M
Investor type
Basic info
Industry
Sectors
Date founded
1973
Investments made
Ascend Gene & Cell Therapies raised $66M on May 9, 2023
Investors: Digitalis Ventures, Ajinomoto Sales (Thailand) Co., Ltd, Cathay Health, -, DCVC Bio and Abingworth
Spruce Biosciences raised $54M on February 9, 2023
Investors: Armistice Capital LLC, RiverVest Venture Partners, 5AM Ventures, Novo Holdings, HealthCap and Abingworth
Pathalys Pharma raised $150M on January 18, 2023
Investors: DaVita Venture Group, Catalys Pacific, OrbiMed Advisors, The Carlyle Group and Abingworth
Entact Bio raised $81M on December 6, 2022
Investors: Qiming Venture Partners USA, Logos Global Management, LP, Surveyor Capital, venBio Partners, Brandon Capital Partners and Abingworth
VenatoRx Pharmaceuticals, Inc. raised $34M on April 4, 2022
Investors: AMR Action Fund and Abingworth
Anjarium Biosciences raised $61M on September 15, 2021
Investors: Gimv, Omega Funds, Surveyor Capital and Abingworth
eFFECTOR Therapeutics, Inc. raised $60M on August 26, 2021
Investors: The Column Group, S.R. One Ltd, Osage University Partners (OUP), Sectoral Asset Management and Abingworth
CymaBay Therapeutics raised $100M on August 2, 2021
Investors: Abingworth
Glycomine Inc. raised $35M on June 23, 2021
Investors: Chiesi Ventures, RiverVest Venture Partners, Remiges Ventures, Inc., Sanofi Ventures, Mission BioCapital, Novo Holdings and Abingworth
X4 Pharmaceuticals raised $55M on March 19, 2021
Investors: Lincoln Park Capital, LLC, Ikarian Capital LLC, OrbiMed Advisors, Driehaus Capital Management LLC, Monashee Investment Management LLC, Altium Capital, Sio Capital Management LLC and Abingworth